SB-431542 [301836-41-9]
Referência HY-10431-10mg
Tamanho : 10mg
Marca : MedChemExpress
Please arrange your schedule properly.
- United States
- Canada
- United Kingdom
- Australia
- Germany
- France
- Japan
- Korea South
- Switzerland
- Algeria
- Argentina
- Austria
- Belgium
- Brazil
- Chile
- Croatia
- Czech Republic
- Denmark
- Finland
- Hong Kong, China
- Hungary
- India
- Iraq
- Ireland
- Israel
- Italy
- Lebanon
- Luxembourg
- Malaysia
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Russia
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Taiwan, China
- Thailand
- Tunisia
- Turkey
- Ukraine
- Macao, China
- Other Countries
SB-431542 est un inhibiteur puissant et sélectif du récepteur ALK5 / TGF-β de type I avec une valeur IC50 de 94 nM.
SB-431542 ist ein wirksamer und selektiver Inhibitor des ALK5/TGF-β-Typ I-Rezeptors mit einem IC50 -Wert von 94 nM.
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Size | Prix | Stock | Quantité |
---|---|---|---|
Solid + Solvent (Highly Recommended) | |||
10 mM * 1 mL
in DMSO
ready for reconstitution
|
En stock | ||
Solution | |||
10 mM * 1 mL in DMSO | En stock | ||
Solid | |||
5 mg | En stock | ||
10 mg | En stock | ||
50 mg | En stock | ||
100 mg | En stock | ||
200 mg | Obtenir un devis | ||
500 mg | Obtenir un devis |
* Veuillez sélectionner la quantité avant d'ajouter des articles.
This product is a controlled substance and not for sale in your territory.
Avis client
Based on 211 publication(s) in Google Scholar
Other Forms of SB-431542:
- SB-431542 (GMP) Obtenir un devis
- SB-431542 (Standard) Obtenir un devis
- •Nat Methods. 2024 Dec 9. [Abstract]
- •Cell. 2024 Nov 14;187(23):6566-6583.e22. [Abstract]
- •Nat Genet. 2024 Feb;56(2):294-305. [Abstract]
- •Immunity. 2022 Mar 15;S1074-7613(22)00124-8. [Abstract]
- •Nat Microbiol. 2024 Jul 29. [Abstract]
- •Nat Biomed Eng. 2022 Nov 24. [Abstract]
- •Cell Metab. 2022 Aug 15;S1550-4131(22)00313-8. [Abstract]
- •Gut. 2022 Jan 7;gutjnl-2021-325018. [Abstract]
- •Mol Cell. 2024 Jul 8:S1097-2765(24)00524-0. [Abstract]
- •Adv Sci (Weinh). 2024 Jul 9:e2402327. [Abstract]
- •Adv Sci (Weinh). 2024 Apr 8:e2306486. [Abstract]
- •Nat Aging. 2024 Mar 15. [Abstract]
- •Nano Today. 2024 Apr, 55, 102201.
- •Chem Eng J. 1 January 2023, 138737.
- •Transl Neurodegener. 2024 Oct 29;13(1):53. [Abstract]
- •J Exp Clin Cancer Res. 2024 Jul 27;43(1):208. [Abstract]
- •Sci Adv. 2023 May 24;9(21):eadg1778. [Abstract]
- •Compos Part B-Eng. 2023 Apr 6, 110711.
- •Redox Biol. 2023 Jun, 102709.
- •J Exp Clin Cancer Res. 2023 Feb 9;42(1):45. [Abstract]
- •Redox Biol. 18 October 2022, 102509.
- •Hepatology. 2022 Mar 27. [Abstract]
- •Exp Mol Med. 2021 Sep 21. [Abstract]
- •Theranostics. 2021 May 13;11(14):7110-7125. [Abstract]
- •Theranostics. 2021 Mar 4;11(9):4483-4501. [Abstract]
- •Cell Rep Med. 2020 Dec 22;1(9):100161. [Abstract]
- •Cancer Res. 2020 Oct 15;80(20):4426-4438. [Abstract]
- •Small. 2020 Jun;16(22):e2001371. [Abstract]
- •Biomaterials. 2020 May;240:119849. [Abstract]
- •EMBO Mol Med. 2020 Jan 9;12(1):e10681. [Abstract]
- •Cancer Res. 2019 Sep 1;79(17):4466-4479. [Abstract]
- •Cell Prolif. 2024 Oct 15:e13765. [Abstract]
- •Am J Hum Genet. 2024 Jul 11.
- •Cell Rep. 2024 Jul 5;43(7):114425. [Abstract]
- •Angiogenesis. 2024 May 21. [Abstract]
- •Cancer Lett. 2024 Jun.
- •Acta Pharmacol Sin. 2024 Mar;45(3):545-557. [Abstract]
- •Cell Prolif. 2024 Jan 12:e13599. [Abstract]
- •Cell Commun Signal. 2024 Jan 5;22(1):17. [Abstract]
- •Sci Total Environ. 2023 Dec 27:912:169613. [Abstract]
- •Cell Prolif. 2023 Dec 2:e13577. [Abstract]
- •Cell Rep. 2023 Oct 10;42(10):113222. [Abstract]
- •Cell Rep. 2023 Jul 11;42(7):112779. [Abstract]
- •Cell Death Dis. 2023 Mar 31;14(3):229. [Abstract]
- •Cell Rep. 2023 Apr 14;42(4):112403. [Abstract]
- •Cell Rep. 2022 Nov 15;41(7):111671. [Abstract]
- •Cell Death Dis. 2022 Mar 2;13(3):202. [Abstract]
- •Cell Death Dis. 2021 Dec 20;13(1):16. [Abstract]
- •Cell Rep. 2020 Apr.
- •Cell Prolif. 2019 Jul;52(4):e12637. [Abstract]
- •Stem Cell Res Ther. 2024 Oct 17;15(1):370. [Abstract]
- •Eur J Med Chem. 2024 Feb 15, 116220.
- •OncoImmunology. 2024 Jan 9.
- •NPJ Regen Med. 2023 Oct 13;8(1):56. [Abstract]
- •Chin Med J. 2023 Jul 15. [Abstract]
- •Biomed Pharmacother. 2023 May 20;164:114920. [Abstract]
- •Biomed Pharmacother. 2023 Mar 15;161:114510. [Abstract]
- •Biomed Pharmacother. 2023 Mar 16;161:114537. [Abstract]
- •Antioxidants (Basel). 2022, 11(12), 2469.
- •J Transl Med. 2022 Nov 12;20(1):523. [Abstract]
- •Antioxid Redox Signal. 2022 Oct 14. [Abstract]
- •Stem Cell Res Ther. 2022 Sep 2;13(1):436. [Abstract]
- •Fundamental Research. 3 June 2022.
- •J Invest Dermatol. 2022 Feb 4;S0022-202X(22)00081-1. [Abstract]
- •Stem Cell Res Ther. 2021 Dec 20;12(1):608. [Abstract]
- •J Transl Med. 2021 Dec 7;19(1):497. [Abstract]
- •Stem Cell Res Ther. 2021 Jun 10;12(1):338. [Abstract]
- •Stem Cell Res Ther. 2021 Jun 11;12(1):345. [Abstract]
- •Br J Pharmacol. 2021 Mar;178(5):1037-1054. [Abstract]
- •Stem Cell Res Ther. 2020 Jun 3;11(1):210. [Abstract]
- •Oncogene. 2020 May;39(22):4450-4464. [Abstract]
- •Stem Cell Res Ther. 2020 Apr 29;11(1):166. [Abstract]
- •Biomed Pharmacother. 2020 May;125:109768. [Abstract]
- •Biomed Pharmacother. 2020 Mar;123:109807. [Abstract]
- •Biomed Pharmacother. 2020 Feb;122:109388. [Abstract]
- •J Med Chem. 2019 Sep 12;62(17):7961-7975. [Abstract]
- •Phytother Res. 2019 Jan;33(1):214-223. [Abstract]
- •Mol Oncol. 2018 Mar;12(3):305-321. [Abstract]
- •Int Immunopharmacol. 2024 Sep 18;142(Pt B):113186. [Abstract]
- •Cells. 2024 Jul 26;13(15):1260. [Abstract]
- •Eur J Pharmacol. 2024 Jun 26:176786. [Abstract]
- •J Biol Chem. 2024 Mar 21:107208. [Abstract]
- •iScience. 2024 Feb 5;27(3):109111. [Abstract]
- •J Ethnopharmacol. 2024 Feb 20:117963. [Abstract]
- •Neurochem Res. 2024 Feb 21. [Abstract]
- •Invest Ophthalmol Vis Sci. 2024 Feb 1;65(2):10. [Abstract]
- •J Biol Chem. 2023 Dec 12:105556. [Abstract]
- •Clin Epigenetics. 2023 Nov 11;15(1):182. [Abstract]
- •J Tradit Complement Med. 2023 Nov 22.
- •Pigment Cell Melanoma Res. 2023 Aug 9. [Abstract]
- •Glycobiology. 2023 Jul 28;cwad062. [Abstract]
- •Mol Neurobiol. 2023 May 10. [Abstract]
- •Neurochem Res. 2023 May 4. [Abstract]
- •Immunol Lett. 2023 May 25;259:1-8. [Abstract]
- •Stem Cells. 2023 Apr 8;sxad028. [Abstract]
- •Int J Mol Sci. 2023 Mar 24.
- •iScience. 2022 Dec 26;26(1):105898. [Abstract]
- •Int J Mol Sci. 2023 Jan 2;24(1):792. [Abstract]
- •Eur J Pharmacol. 2022: 175476.
- •J Biol Chem. 2022: 102843.
- •Front Nutr. 2022 Oct 11;9:998662. [Abstract]
- •Front Nutr. 27 May 2022.
- •Respir Res. 2022 Mar 25;23(1):70. [Abstract]
- •Int Immunopharmacol. 2022 Apr 20;108:108777. [Abstract]
- •Stem Cell Rev Rep. 2022 Jan 26. [Abstract]
- •Biomedicines. 2021 Nov 15;9(11):1692. [Abstract]
- •Front Cell Dev Biol. 2021 Jun 18;9:659389. [Abstract]
- •J Biol Chem. 2021 Oct 13;101303. [Abstract]
- •Toxins. 2021 Aug 22;13(8):585. [Abstract]
- •Front Cell Dev Biol. 2021 May 31;9:667252. [Abstract]
- •Bioorg Chem. 2021, 105222.
- •Front Pharmacol. 2021 Mar 25;12:644638. [Abstract]
- •J Ethnopharmacol. 2021 Jan 29;113893. [Abstract]
- •Aging. 2020 Oct 25;12(20):20047-20068. [Abstract]
- •Mol Cell Endocrinol. 2021 Jan 1;519:111055. [Abstract]
- •FASEB J. 2020 Oct;34(10):13461-13473. [Abstract]
- •Skelet Muscle. 2020 May 2;10(1):13. [Abstract]
- •J Cell Mol Med. 2020 May;24(9):5195-5204. [Abstract]
- •Mol Carcinog. 2020 Jun;59(6):651-660. [Abstract]
- •Sci Rep. 2020 Jan 28;10(1):1281. [Abstract]
- •Neurotherapeutics. 2020 Apr;17(2):690-703. [Abstract]
- •J Ethnopharmacol. 2020 Mar 1;249:112404. [Abstract]
- •Clin Sci. 2019 Oct 30;133(20):2069-2084. [Abstract]
- •J Cell Physiol. 2020 Apr;235(4):3558-3568. [Abstract]
- •J Cell Physiol. 2020 Mar;235(3):2655-2667. [Abstract]
- •FEBS J. 2020 Feb;287(4):783-799. [Abstract]
- •J Biol Chem. 2019 Oct 25;294(43):15808-15825. [Abstract]
- •Sci Rep. 2019 Mar 5;9(1):3462. [Abstract]
- •Stem Cells. 2019 Feb;37(2):190-201. [Abstract]
- •Molecules. 2019 Jan 2;24(1):144. [Abstract]
- •Immunol Lett. 2019 Feb;206:33-40. [Abstract]
- •Int J Mol Med. 2018 Dec;42(6):3395-3403. [Abstract]
- •J Cell Mol Med. 2018 Sep;22(9):4354-4365. [Abstract]
- •Int J Mol Sci. 2018 May 23;19(6). pii: E1556. [Abstract]
- •Mol Cell Biochem. 2018 Feb;439(1-2):117-129. [Abstract]
- •Int J Mol Sci. 2017 Apr 18;18(4). pii: E853. [Abstract]
- •Int Immunopharmacol. 2015 Sep;28(1):707-14. [Abstract]
- •Genes (Basel). 2024 Oct 30;15(11):1400. [Abstract]
- •Int Dent J. 2024 Oct 10:S0020-6539(24)01538-7. [Abstract]
- •J Anim Sci. 2024 Aug 27.
- •Cell Rep Methods. 2024 Aug 27:100843. [Abstract]
- •Funct Integr Genomics. 2024 Jul 12;24(4):123. [Abstract]
- •Cell Rep Methods. 2024 May 8:100777. [Abstract]
- •Pharm Biol. 2023 Dec;61(1):1332-1342. [Abstract]
- •Braz J Med Biol Res. 2023 Jul 21;56:e12203. [Abstract]
- •Braz J Otorhinolaryngol. 2023 Feb 14;S1808-8694(23)00007-1. [Abstract]
- •Exp Cell Res. 2023 Jan 24;424(1):113492. [Abstract]
- •Brain Res. 2022 Oct 13;148126. [Abstract]
- •Clin Cosmet Investig Dermatol. 2022 Aug 6;15:1561-1573. [Abstract]
- •J Pers Med. 2022, 12(3), 385.
- •Dig Dis Sci. 2021 Nov 19. [Abstract]
- •J Tissue Eng Regen Med. 2021 Aug 7. [Abstract]
- •Steroids. 2021, 108887.
- •Cancer Manag Res. 2021 May 7;13:3685-3697. [Abstract]
- •Animals. 2021 Feb 6;11(2):425. [Abstract]
- •Exp Ther Med. 2021 Feb 25.
- •J Mater Sci Mater Med. 2020 Nov 30;31(12):130. [Abstract]
- •J Mol Histol. 2021 Feb;52(1):77-86. [Abstract]
- •Am J Reprod Immunol. 2021 Mar;85(3):e13344. [Abstract]
- •Mol Med Rep. 2019 Mar;19(3):2107-2114. [Abstract]
- •Exp Eye Res. 2019 Mar 23;182:44-56. [Abstract]
- •Onco Targets Ther. 2018 Nov 21;11:8251-8263. [Abstract]
- •Oncol Lett. 2018 Jun;15(6):9681-9686. [Abstract]
- •Brain Res Bull. 2018 May;139:38-47. [Abstract]
- •Oncol Lett. 2018 Mar;15(3):2801-2806. [Abstract]
- •Oncol Lett. 2017 Jul;14(1):541-546. [Abstract]
- •Acta Histochem. 2015 Jul;117(6):551-558. [Abstract]
- •Acta Cir Bras. 2023 Dec 1:38:e385123. [Abstract]
- •Patent. US20240247230A1.
- •Authorea. 2024 Jul 16.
- •bioRxiv. 2024 August 30.
- •Methods Mol Biol. 2024:2824:409-424. [Abstract]
- •Res Sq. 2024 Jun 03.
- •Res Sq. 2024 May 20.
- •bioRxiv. 2024 Mar 31.
- •bioRxiv. 2024 Feb 18.
- •bioRxiv. 2024 Jan 5.
- •SSRN. 2023 Sep 15.
- •Research Square Preprint. 2023 Aug 30.
- •bioRxiv. 2023 Aug 22.
- •SSRN. 2023 Mar 3.
- •Methods Mol Biol. 2022 Dec 15. [Abstract]
- •Research Square Print. October 24th, 2022.
- •Research Square Print. September 15th, 2022.
- •Research Square Print. 2022 Jul.
- •Authorea. January 12, 2022.
- •Research Square Preprint. 2021 Sep.
- •Research Square Preprint. 2021 May.
- •Research Square Preprint. 2021 Apr.
- •bioRxiv. 2021 Feb 25.
- •Research Square Preprint. 2020 Aug.
- •Brain Hemorrhages. 2020 Jul.
- •School of Medical Sciences. University of Sydney. 2018 Jul.
- •Chin J Immun. 2016 (5): 615-619.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Mar 16;161:114537. [Abstract]
- SB431542 (4.2 mg/kg; i.p.; single daily for 3 days) reduces the expression of α-SMA, collagen-I and p-Smad3 in SiO2-induced fibrosis lungs of mice.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Stem Cells. 2019 Feb;37(2):190-201. [Abstract]
- Western blot images show Smad2/3 phosphorylation is lower than baseline in the sh-GPM6B cells and higher than baseline in the GPM6B-sgRNA cells. The phosphorylation of Smad2/3 in the sh-GPM6B TGF-β1 group is elevated by Alantolactone and the phosphorylation is reduced by treatment with SB431542.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Stem Cells. 2019 Feb;37(2):190-201. [Abstract]
- Western blot analyses show the repression of SMC specific markers in the sh-GPM6B TGF-β1 group are abolished by Alantolactone in the sh-GPM6B and the enrichment of SMC specific markers in the GPM6B-sgRNA cells is cancelled by treatment with SB431542.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2019 Mar;19(3):2107-2114. [Abstract]
- Effects of the TGF‑β1 inhibitor SB (20 μM) on mechanical force‑induced COL‑1 and MMP‑1 mRNA expression.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Phytother Res. 2019 Jan;33(1):214-223. [Abstract]
- Western analysis of FN and α-SMA in cardiac fibroblasts or NIH3T3 with treatments of (+)‐isobicyclogermacrenal, spathulenol, oxymatrine (OMT), and SB431542 at indicated concentrations.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2018 Mar;12(3):305-321. [Abstract]
- Western blot analysis of EGFR, total and phosphorylated Smad3, total and phosphorylated ERK protein expression in cell lysates from two breast cancer cells pretreated with SB431542 and then stimulated with TGF-β for the indicated times.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2018 May 23;19(6). pii: E1556. [Abstract]
- E-cadherin, N-cadherin, Snail, and MMP-2 expression in HCC cells is examined by Western blot analysis. GAPDH is used as a loading control.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2018 Sep;22(9):4354-4365. [Abstract]
- p-FOXO3a (Thr32), p-FOXO3a (Ser253), FOXO3a, p-Akt and Akt expression via western blot following treatment with PBS, ASV, TGF-b1, TGF-b1+ASV, TGF-b1+SB431542 or TGF-b1+LY294002.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Immunol Lett. 2019 Feb;206:33-40. [Abstract]
- Monocytes were cultured with 20 ng/mL M-CSF with or without 10 ng/mL TGF-β1 for 2 days, with SB431542 (1 or 50 μM) or SIS3 (2.5 μM) having been added 30 min beforehand. Whole-cell lysates were subjected to SDS-PAGE and immunoblotted.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2018 Feb;439(1-2):117-129. [Abstract]
- Protein expression levels of E-cadherin N-cadherin, p-ERK, ERK, TGF-β1, p-Smad2, and p-Smad3 in each group are analyzed by western blotting.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Brain Res Bull. 2018 May;139:38-47. [Abstract]
- pSmad2/3 protein levels are down-regulated by the ALK5 inhibitor SB431542 (rGDF11 group vs. rGDF11+SB group, p=0.000).
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Mar;15(3):2801-2806. [Abstract]
- A549 cells are co cultured with 10.0 mM SB431542 for 48 h, the expression of TGF β1, Smad2 and caspase 3 are tested by western blot analysis and then analyzed.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Jun;15(6):9681-9686. [Abstract]
- A549 cells are treated with 1.0% CSE with or without 10.0 mM SB431542 for 48 h, the levels of TGF β1, p Smad2, and MMP3 is assayed by western blot analysis.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2017 Apr 18;18(4). pii: E853. [Abstract]
- The protein level of Six2 and Ki67 after the treatment of phosphorylation Smad3 ( p-Smad3) inhibitor SB431542 (10 µM) for 48 h.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2017 Jul;14(1):541-546. [Abstract]
- To investigate the effect of SB431542 on the accumulation of TGFβ1 and MMP3 in MM cells, RPMI 8226 cells are treated with 10, 100 and 1,000 nmol/mL SB431542 for 48 h. Western blotting is performed. The results demonstrate that SB431542 significantly decreases the accumulation of TGFβ1 and MMP3 at 100 and 1,000 nmol/mL when compared with the control. Smad2, as a signaling molecule, can be initially activated by TGFβ1. Therefore, the effect of SB431542 on the expression of Smad2 and p-Smad2 in RPM
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Chin J Immun. 2016 (5): 615-619.
- 10-1000 nM of SB431542 are co-cultured with RLE-6TN cells for 48 h. Expressions of p-Smad2 and Smad are detected by Western blot.
-
SB-431542 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2015 Sep;28(1):707-14. [Abstract]
- SB431542 is used to block the TGF-β1/Smad2 pathway and the expression of PLTP, p-Smad2 and cleaved caspase-3 is analyzed. (A) RLE-6TN cells are treated with 5–500 nM SB431542 for 72 h. Expression of PLTP and p-Smad2 is analyzed by Western blot. (B) CSE-treated rat lung epithelial cells are treated with 500 nM SB431542 to block the TGF-β1/Smad2 pathway.
Voir tous les produits spécifiques à Isoform TGF-β Receptor:
Activité biologique
Pureté et documentation
Références
Avis client
Description |
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways[1][2][3]. |
||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||||||||||||||||||
Cellular Effect |
|
||||||||||||||||||||||||||||||||
In Vitro |
SB-431542 can inhibit the activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
Apoptosis Analysis[2]
Cell Invasion Assay[2]
Cell Migration Assay [2]
|
||||||||||||||||||||||||||||||||
In Vivo |
SB-431542 (subconjunctival; 0.5 and 2 mM; on days 1, 2, 3, and 7) inhibits scar formation after glaucoma filtration surgery in New Zealand rabbits[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||||||||||
Masse moléculaire |
384.39 |
||||||||||||||||||||||||||||||||
Formule |
C22H16N4O3 |
||||||||||||||||||||||||||||||||
CAS No. | |||||||||||||||||||||||||||||||||
Appearance |
Solid |
||||||||||||||||||||||||||||||||
Color |
Off-white to yellow |
||||||||||||||||||||||||||||||||
SMILES |
O=C(C1=CC=C(C=C1)C2=NC(C3=CC=C4OCOC4=C3)=C(N2)C5=NC=CC=C5)N |
||||||||||||||||||||||||||||||||
Livraison | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||||||||||
Stockage |
|
||||||||||||||||||||||||||||||||
Solvant et solubilité |
In Vitro:
DMSO : ≥ 100 mg/mL (260.15 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Ethanol : 11.17 mg/mL (29.06 mM; Need ultrasonic and warming) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||||||||||||||||||||||
Pureté et documentation | |||||||||||||||||||||||||||||||||
Références |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
Ethanol / DMSO | 1 mM | 2.6015 mL | 13.0076 mL | 26.0152 mL | 65.0381 mL |
5 mM | 0.5203 mL | 2.6015 mL | 5.2030 mL | 13.0076 mL | |
10 mM | 0.2602 mL | 1.3008 mL | 2.6015 mL | 6.5038 mL | |
15 mM | 0.1734 mL | 0.8672 mL | 1.7343 mL | 4.3359 mL | |
20 mM | 0.1301 mL | 0.6504 mL | 1.3008 mL | 3.2519 mL | |
25 mM | 0.1041 mL | 0.5203 mL | 1.0406 mL | 2.6015 mL | |
DMSO | 30 mM | 0.0867 mL | 0.4336 mL | 0.8672 mL | 2.1679 mL |
40 mM | 0.0650 mL | 0.3252 mL | 0.6504 mL | 1.6260 mL | |
50 mM | 0.0520 mL | 0.2602 mL | 0.5203 mL | 1.3008 mL | |
60 mM | 0.0434 mL | 0.2168 mL | 0.4336 mL | 1.0840 mL | |
80 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.8130 mL | |
100 mM | 0.0260 mL | 0.1301 mL | 0.2602 mL | 0.6504 mL |
SB-431542 Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
SB-431542301836-41-9SB431542SB 431542OrganoidTGF-β ReceptorApoptosisTransforming growth factor beta receptorsTGF-β receptor kinase inhibitor (TRKI)ALK4ALK5ALK7transcriptiongene expressionapoptosisgrowth suppressioncancersignal transduction pathwaysInhibitorinhibitorinhibit
Vos produits récemment consultés:
Demande en ligne
Your information is safe with us. * Required Fields.
Bulk Inquiry
Inquiry Information
- Nom du produit:
- SB-431542
- Cat. No.:
- HY-10431
- Quantité:
- MCE Japan Authorized Agent: